ArticleCancer letters2009
Highly homologous hS100A15 and hS100A7 proteins are distinctly expressed in normal breast tissue and breast cancer.
Article in Cancer letters, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 34 citations in OpenAlex.
- Tetraspanin CD82 Correlates with and May Regulate S100A7 Expression in Oral Cancer.International journal of molecular sciences · 2024Article
- S100 Proteins as Novel Therapeutic Targets in Psoriasis and Other Autoimmune Diseases.Molecules (Basel, Switzerland) · 2022Review
- Assessment of Phenylboronic Acid Nitrogen Mustards as Potent and Selective Drug Candidates for Triple-Negative Breast Cancer.ACS pharmacology & translational science · 2021Article
- GATA3 somatic mutations are associated with clinicopathological features and expression profile in TCGA breast cancer patients.Scientific reports · 2021Article
- Unique epithelial expression of S100A calcium binding protein A7A in the endometrium at conceptus implantation in pigsAsian-Australasian journal of animal sciences · 2019Article
- Article
- Th17 micro-milieu regulates NLRP1-dependent caspase-5 activity in skin autoinflammation.PloS one · 2017Article
- Interleukin-6 is a potential therapeutic target in interleukin-6 dependent, estrogen receptor-α-positive breast cancer.Breast cancer (Dove Medical Press) · 2016Article
- The Clinical Significance and Molecular Features of the Spatial Tumor Shapes in Breast Cancers.PloS one · 2015Article
- Large-scale proteomics differentiates cholesteatoma from surrounding tissues and identifies novel proteins related to the pathogenesis.PloS one · 2014Article
- S100 protein family in human cancer.American journal of cancer research · 2014Review
- Opposing functions of psoriasin (S100A7) and koebnerisin (S100A15) in epithelial carcinogenesis.Current opinion in pharmacology · 2013Review
- Article
- Structural characterization of S100A15 reveals a novel zinc coordination site among S100 proteins and altered surface chemistry with functional implications for receptor binding.BMC structural biology · 2012Article
- S100A7 enhances mammary tumorigenesis through upregulation of inflammatory pathways.Cancer research · 2012Article
- The expression of Psoriasin (S100A7) and CD24 is linked and related to the differentiation of mammary epithelial cells.PloS one · 2012Article
- Distinct innate immune gene expression profiles in non-melanoma skin cancer of immunocompetent and immunosuppressed patients.PloS one · 2012Article
- Novel S100A7 (psoriasin)/S100A15 (koebnerisin) subfamily: highly homologous but distinct in regulation and function.Amino acids · 2011Review
- The role of S100 genes in breast cancer progression.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2011Article
- Gene from a psoriasis susceptibility locus primes the skin for inflammation.Science translational medicine · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 2 countries.
Funding
Abstract
Human S100A7 (psoriasin) is considered a marker for specific stages of breast cancer. hS100A15 is almost identical to hS100A7 and difficult to discriminate. We developed specific probes to distinguish hS100A7 and hS100A15, and demonstrate their differential distribution in normal breast tissue. Further, hS100A7 and S100A15 transcripts are elevated in ER/PR negative breast cancers, but hS100A15 protein is detected in all cancer specimens while hS100A7 protein is sporadically expressed. The differential regulation, expression and distribution of hS100A7 and hS100A15 and their reported distinct functions are compelling reasons to discriminate among these proteins in normal breast and breast cancers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.